TW200714604A - Substituted heterocycles and the uses thereof - Google Patents

Substituted heterocycles and the uses thereof

Info

Publication number
TW200714604A
TW200714604A TW095112162A TW95112162A TW200714604A TW 200714604 A TW200714604 A TW 200714604A TW 095112162 A TW095112162 A TW 095112162A TW 95112162 A TW95112162 A TW 95112162A TW 200714604 A TW200714604 A TW 200714604A
Authority
TW
Taiwan
Prior art keywords
inhibitory activity
substituted heterocycles
novel compounds
kinase inhibitory
prophylaxis
Prior art date
Application number
TW095112162A
Other languages
English (en)
Inventor
Kevin Daly
Alexander Hird
Stephanos Ioannidis
James Janetka
Paul Lyne
Dorin Toader
Melissa Vasbinder
Dingwei Yu
Yan Yu
Nicola Heron
Jamie Scott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36586532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200714604(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200714604A publication Critical patent/TW200714604A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW095112162A 2005-04-06 2006-04-06 Substituted heterocycles and the uses thereof TW200714604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66877905P 2005-04-06 2005-04-06
US73886605P 2005-11-21 2005-11-21

Publications (1)

Publication Number Publication Date
TW200714604A true TW200714604A (en) 2007-04-16

Family

ID=36586532

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095112162A TW200714604A (en) 2005-04-06 2006-04-06 Substituted heterocycles and the uses thereof

Country Status (15)

Country Link
US (1) US20090275570A1 (zh)
EP (1) EP1869052A1 (zh)
JP (1) JP2008534664A (zh)
KR (1) KR20080009200A (zh)
AR (1) AR053352A1 (zh)
AU (1) AU2006232620A1 (zh)
BR (1) BRPI0608659A2 (zh)
CA (1) CA2601983A1 (zh)
IL (1) IL186112A0 (zh)
MX (1) MX2007012448A (zh)
NO (1) NO20074634L (zh)
RU (1) RU2007140734A (zh)
TW (1) TW200714604A (zh)
UY (1) UY29458A1 (zh)
WO (1) WO2006106326A1 (zh)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
JP5015166B2 (ja) * 2005-11-08 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕ５受容体アンタゴニストとしてのチアゾロ［４，５−ｃ］ピリジン誘導体
WO2007062318A2 (en) * 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US7994321B2 (en) 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
WO2008024725A1 (en) * 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
EP2069359B1 (en) * 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US20110294782A1 (en) * 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2008132500A2 (en) * 2007-04-27 2008-11-06 Astrazeneca Ab Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
PE20090362A1 (es) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina como moduladores de dgat
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2707491A1 (en) * 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
EP2242757B1 (en) 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US7998688B2 (en) 2008-03-07 2011-08-16 OSI Pharmaceuticals, LLC Inhibition of EMT induction in tumor cells by anti-cancer agents
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
EP2177510A1 (en) * 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
ES2481791T3 (es) * 2009-09-18 2014-07-31 Zhanggui Wu Compuestos novedosos y uso terapéutico para la inhibición de proteína cinasa
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
TW201304778A (zh) 2010-11-16 2013-02-01 Array Biopharma Inc 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
HK1215579A1 (zh) 2012-11-29 2016-09-02 Karyopharm Therapeutics, Inc. 被取代的2，3-二氫苯並呋喃基化合物和其用途
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
EP3483167A1 (en) * 2013-06-26 2019-05-15 AbbVie Inc. Primary carboxamides as btk inhibitors
CN108440515B (zh) 2013-07-03 2022-05-03 卡尔约药物治疗公司 取代的苯并呋喃基和苯并噁唑基化合物及其用途
WO2015042414A1 (en) * 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
EP2865757A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
US10266526B2 (en) * 2014-09-10 2019-04-23 Epizyme, Inc. Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
AR102426A1 (es) * 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
WO2016100515A1 (en) * 2014-12-16 2016-06-23 Karyopharm Therapeutics Inc. Cyclic compounds and uses thereof
EP3932914A1 (en) 2015-03-13 2022-01-05 Valo Health, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
AU2019435745B2 (en) * 2019-03-18 2026-01-22 The Council Of The Queensland Institute Of Medical Research Cardiomyocyte proliferation
WO2021141974A2 (en) * 2020-01-07 2021-07-15 Fan Wu Combination cancer therapy using chk inhibitor
WO2022146698A1 (en) * 2020-12-29 2022-07-07 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
CN113816970B (zh) * 2021-09-18 2022-08-09 济宁医学院附属医院 一种选择性铜离子螯合剂、其制备方法及其在肺纤维化中的应用
CN113861215B (zh) * 2021-09-18 2022-05-17 济宁医学院附属医院 一种选择性铜离子螯合剂、其制备方法及其在结直肠癌中的应用
TW202507551A (zh) * 2022-01-19 2025-02-16 美商Ｄ２Ｓ公司 用於執行設計規則核對檢查的方法、機器可讀取媒體及系統

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
US20050148643A1 (en) * 2003-08-19 2005-07-07 Agouron Pharmaceuticals, Inc. Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme

Also Published As

Publication number Publication date
AR053352A1 (es) 2007-05-02
BRPI0608659A2 (pt) 2010-11-30
WO2006106326A1 (en) 2006-10-12
EP1869052A1 (en) 2007-12-26
IL186112A0 (en) 2008-01-20
CA2601983A1 (en) 2006-10-12
MX2007012448A (es) 2007-10-19
AU2006232620A1 (en) 2006-10-12
KR20080009200A (ko) 2008-01-25
WO2006106326A8 (en) 2007-11-29
UY29458A1 (es) 2006-11-30
RU2007140734A (ru) 2009-05-20
JP2008534664A (ja) 2008-08-28
US20090275570A1 (en) 2009-11-05
NO20074634L (no) 2007-10-31

Similar Documents

Publication Publication Date Title
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
IL185391A0 (en) Quinazolinone t-type calcium channel antagonists
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
GB0625648D0 (en) Compounds
ATE520668T1 (de) Sigmarezeptor-inhibitoren
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
TW200738659A (en) Novel compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200700064A (en) Novel compounds